InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | 2026-05-13 | Slosman Marvin | Director & CEO and President | Purchase | 21.0K | $1.20 | $25K | 3.56M | View ↗ | |
| 2026-05-11 | 2026-05-12 | Stuka Paul | Director | Purchase | 10.0K | $1.19 | $12K | 632.9K | View ↗ | |
| 2026-05-08 | 2026-05-12 | Stuka Paul | Director | Purchase | 65.6K | $1.16 | $76K | 622.9K | View ↗ | |
| 2026-05-07 | 2026-05-08 | Ward Scott R. | Director | Purchase | 73.3K | $1.15 | $84K | 237.1K | View ↗ | |
| 2026-05-07 | 2026-05-08 | Stuka Paul | Director | Purchase | 6,378 | $1.15 | $7K | 531.6K | View ↗ |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| REVENUES | $9.0M+28.1% | $7.0M+13.0% | $6.2M+20.0% | $5.2M |
| COST OF REVENUES | $6.3M+15.0% | $5.5M+25.1% | $4.4M+8.5% | $4.1M |
| GROSS PROFIT | $2.6M+75.9% | $1.5M-16.7% | $1.8M+61.8% | $1.1M |
| Research and development | $15.0M+10.0% | $13.6M+70.8% | $8.0M+2.2% | $7.8M |
| Selling and marketing | $16.6M+172.7% | $6.1M+57.0% | $3.9M+5.5% | $3.7M |
| General and administrative | $20.7M+35.3% | $15.3M+37.8% | $11.1M+32.9% | $8.4M |
| Total operating expenses | $52.3M+49.3% | $35.0M+52.5% | $22.9M+15.7% | $19.8M |
| LOSS FROM OPERATIONS | -$49.6M-48.1% | -$33.5M-58.5% | -$21.1M-13.0% | -$18.7M |
| FINANCIAL INCOME, net: | $891K-42.8% | $1.6M+20.5% | $1.3M+416.8% | $250K |
| LOSS BEFORE TAX EXPENSES | -$48.7M-52.5% | -$31.9M-60.9% | -$19.9M-7.5% | -$18.5M |
| TAX EXPENSES | $63K+6.8% | $59K-9.2% | $65K+132.1% | $28K |
| NET LOSS | -$48.8M-52.4% | -$32.0M-60.7% | -$19.9M-7.7% | -$18.5M |
| NET LOSS PER SHARE - basic | -$760+0.0% | -$760+7.3% | -$820+65.1% | -$2K |
| NET LOSS PER SHARE - diluted | -$760+0.0% | -$760+7.3% | -$820+65.1% | -$2K |
| WEIGHTED AVERAGE NUMBER OF COMMON STOCK USED IN COMPUTING NET LOSS PER SHARE - basic | $64.33B+53.4% | $41.93B+72.8% | $24.27B+208.3% | $7.87B |
| WEIGHTED AVERAGE NUMBER OF COMMON STOCK USED IN COMPUTING NET LOSS PER SHARE - diluted | $64.33B+53.4% | $41.93B+72.8% | $24.27B+208.3% | $7.87B |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
InspireMD to Participate in Upcoming Bank of America Securities 2026 Global Healthcare Conference
InspireMD, Inc. Q1 2026 Earnings Call Summary
InspireMD anticipates FDA approval of original CGuard delivery system in Q3 2026 as it withdraws 2026 revenue guidance
InspireMD, Inc. (NSPR) Q1 2026 Earnings Call Transcript